Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Nan Fung Group Holdings Ltd

Nan Fung Group Holdings Ltd grew its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 183.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,875 shares of the company's stock after purchasing an additional 20,000 shares during the period. Kymera Therapeutics comprises approximately 1.0% of Nan Fung Group Holdings Ltd's investment portfolio, making the stock its 25th largest holding. Nan Fung Group Holdings Ltd's holdings in Kymera Therapeutics were worth $1,242,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. lifted its position in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares in the last quarter. KBC Group NV grew its holdings in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after buying an additional 752 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after buying an additional 406 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth about $251,000. Finally, PEAK6 LLC acquired a new position in Kymera Therapeutics during the fourth quarter worth about $302,000.

Kymera Therapeutics Trading Up 7.0 %

NASDAQ:KYMR traded up $2.16 during midday trading on Thursday, reaching $32.86. The company had a trading volume of 822,398 shares, compared to its average volume of 554,453. Kymera Therapeutics, Inc. has a 12-month low of $19.45 and a 12-month high of $53.27. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -14.10 and a beta of 2.22. The stock's fifty day simple moving average is $30.03 and its 200-day simple moving average is $38.73.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Activity

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KYMR has been the topic of several recent research reports. HC Wainwright boosted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Leerink Partners reiterated an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th. Finally, Citigroup started coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.